FREMONT, Calif.--(BUSINESS WIRE)--DiscoveRx Corporation today announced the launch of BROMOscanSM, a new service platform for identification and optimization of inhibitors targeting bromodomain epigenetic “reader” proteins. Developed in a scientific collaboration with the laboratory of James Bradner, MD, at Dana-Farber Cancer Institute in Boston, the new platform is based on the proven KINOMEscanSM technology and will drive lead discovery and optimization programs by enabling researchers to rapidly and quantitatively characterize potential inhibitors across a diversity of bromodomains. BROMOscan can be applied to high throughput screening, selectivity profiling and quantitative affinity (Kd) determinations across several bromodomain families, including the BET family.
